Back to Agenda
Behavioral and Educational Strategies for Avoiding Falsified Medicine Exposure (BE SAFE)
Session Chair(s)
Lubna Merchant, PHARMD, MS
Risk Management Strategy, AbbVie, United States
Counterfeit drugs are important public health concern that impact both developed and LMICs. The session is to understand the current landscape and global impact of these and hear from industry, regulators and others on best approaches to address this
Learning Objective : Discuss the significance and current landscape of counterfeit (falsified) medicines; Describe the economic, socio-economic and pervasive health threats to the global population from counterfeit products; Identify the current interventions implemented by regulators, industry, policy makers to combat this; Recognize new approaches to develop more focused programs that address the root cause.
Speaker(s)
Saifuddin Ahmed, MD, PHD
Professor, Department of Population, Family, and Reproductive Health, Johns Hopkins University, United States
Academic Update
Rutendo Kuwana, RPH
Team Lead, Incidents and Substandard/Falsified Medical Products, World Health Organization (WHO), Switzerland
WHO Update
Sangeeta Chatterjee
Deputy Office Director, Office of Drug Security, Integrity, Response, OC, CDER, FDA, United States
FDA Update
Regina Mariam Kamoga, MPA
Executive Director, Community Health And Information Network ( CHAIN), Uganda
Patient Perspective
Have an account?